Dimensional Fund Advisors’s Maze Therapeutics MAZE Stock Holding History

Dimensional Fund Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.73M	Buy	+100,556	New	+$2.79M	﹤0.01%	2644

Other funds holding MAZE

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Mass General Brigham Somerville, Massachusetts $456M AUM 27.51% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Dimensional Fund Advisors's MAZE Position: Q3 2026 in Review

Dimensional Fund Advisors opened a new position in Maze Therapeutics (MAZE) in Q3 2026: 100,556 shares worth $2.73M. The stake represents ﹤0.01% of the portfolio and ranks #2644 among its holdings.

44 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

Dimensional Fund Advisors held 100,556 shares of Maze Therapeutics worth $2.73M as of Q3 2026.
Maze Therapeutics was a new Dimensional Fund Advisors position in Q3 2026.
Maze Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2644 holding.
44 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.